Prestige Consumer Healthcare Inc. reported $1.09bn in revenues for its fiscal year 2022, up 15.2%, as its fourth-quarter income jumped more than 45% despite the inflationary pressures as it avoided supply chain and shipping bottlenecks hitting many other consumer health product companies.
Prestige Consumer Supply Chain Prowess Helps Offset Inflationary Pressures For Record Results
After a company-record FY2022, Prestige CEO Ron Lombardi says future inflationary pressures and supply chain issues should be “manageable.”
More from Earnings
• By
Arkopharma's parent company Dermapharm is undertaking a strategic shift at the French firm to help it better compete in the dietary supplements market after a tough year.
• By
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
• By
Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.
• By
UK-based consumer health giant reports organic sales growth of 5.0% in 2024 as gains for its power brands offset a softer cold & flu season, particularly in the US.
More from Business
• By
By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”